IDP Pharma´s CEO will participate as an expert guest at the European Drug Discovery Innovation & Outsourcing program conference that will be held in Barcelona on September 12 and 13, 2023. We invite you to reserve 1:1 business meetings to enhance commercial partnerships with IDP Pharma.

IDP Pharma has entered into a licensed option with a USA based Biotech for IDP-602, a first in class drug targeting IDPs driving eye diseases. The company is responsible to develop IDP-602 across preclinical and formulation work prior to executing a license option. IDP Pharma consolidates its position in cancer while its partners expand applications

IDP Pharma, in collaboration with Carlos III Research Institute (ISCIII) and Hospital 12 de Octubre in Madrid, has published a study in the journal Neurotherapeutics (https://link.springer.com/article/10.1007/s13311-021-01176-6) which reveals that a new experimental drug, IDP-410, directly engages the key oncoprotein N-MYC and reduces the growth of glioblastomas in animal models. The Company expects to develop further

IDP Pharma will present at the Annual Meeting of the American Association for Cancer Research (June 22-24) its first in class c-Myc inhibitor program, expected to enter clinical trails in 2021. Quando sono tornato a casa, i medici hanno scoperto che il mio cuore era ingrossato e che soffrivo di tubercolosi, un’infezione mortale e fatale

Bio€quity 2019, the most important biopharmaceutical investor conference in Europe, will take place in Barcelona for the first time on May 20-21, 2019. IDP Pharma will attend The meeting and present the company to investors. Organized by BioCentury and EBD Group is the seminal industry event for financial dealmakers looking for investor-validated life science companies